ThomasMarronMDPhD

Thoracic Cancer

Professor of Medicine, Hematology and Oncology; Professor of Immunology and Immunotherapy; Director, Early Phase Trials Unit; The Tisch Cancer Center - Icahn School of Medicine at Mount Sinai

Request Appointment

Overview of Dr. Marron

Dr. Thomas Marron is an oncologist in New York, NY and is affiliated with The Mount Sinai Hospital. He received his medical degree from Icahn School of Medicine at Mount Sinai and has been in practice 5 years. He is one of 189 doctors at The Mount Sinai Hospital who specialize in Oncology. He has more than 70 publications and over 500 citings.

Office
10 E 102nd St
New York, NY 10029
Book by Phone+1(415) 630-2117

Fax+1 212-423-0522

Education & Training

Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 2014 - 2017
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2012 - 2014
Icahn School of Medicine at Mount SinaiClass of 2012
Mount Sinai Graduate School of Biological SciencesPhD

Certifications & Licensure

NY State Medical License 2013 - 2026
NJ State Medical License 2022 - 2023
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) Start of enrollment: 2020 Mar 05
Completed
Phase 2
Interferon Lambda Therapy for COVID-19 Start of enrollment: 2020 Sep 01
Withdrawn
Phase 2
Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma Start of enrollment: 2020 Aug 19
Recruiting
Phase 1
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies Start of enrollment: 2020 Oct 12
Active, not recruiting
Phase 1
Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma Start of enrollment: 2021 Jun 01
Active, not recruiting
Phase 2
Roles: Contact
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC Start of enrollment: 2024 Mar 08
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Dupilumab_Metastatic NSCLC Start of enrollment: 2021 Sep 10
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator, Sponsor-Investigator
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer Start of enrollment: 2023 Aug 08
Recruiting
Phase 2, Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
Hematopoietic aging promotes cancer by fueling IL-1⍺-driven emergency myelopoiesis.
Matthew D Park, Jessica Le Berichel, Pauline Hamon, C Matthias Wilk, Meriem Belabed
Science. 2024-10-25
1594 citations
An inflammatory cytokine signature predicts COVID-19 severity and survival.
Diane Marie Del Valle, Seunghee Kim-Schulze, Hsin-Hui Huang, Noam D. Beckmann, Sharon Nirenberg
Nature Medicine. 2020-08-24
35 citations
An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis.
Nelson M LaMarche, Samarth Hegde, Matthew D Park, Barbara B Maier, Leanna Troncoso
Nature. 2024-01-01

Press Mentions

Alligator Bioscience: First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor TrialNovember 11th, 2024
Eczema Drugs Could Counter Ovarian Cancer’s IL-4-Based Immunotherapy ResistanceOctober 31st, 2024
Study Finds Eczema-Linked Protein Helps Ovarian Cancer Survive, Suggesting Potential for Skin Drug-Based TreatmentOctober 30th, 2024
Join now to see all